You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
Help Center
uSMARTPORT
Download
About
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

Jacobio Pharmaceuticals Group Co., Ltd. (01167)

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies. Its clinical stage candidates include Glecirasib (JAB-21822), a KRAS G12C inhibitor under various stage studies for indications, such as NSCLC, PDAC, CRC, and other solid tumors; Sitneprotafib (JAB-3312), an SHP2 inhibitor that is in Phase III trials for NSCLC indication; JAB-23E73

Business Collaboration
Register now

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
Email: cs@usmart.hk
WhatsApp: +852 5989 2641
uSMART-Facebook-Page
Headquarters
Sheung Wan
Address:
Room 2405-06, 24/F, 308 Central Des Voeux, Sheung Wan, Hong Kong
(3-mins walk from MTR Sheung Wan Station Exit A2)
North District
Address:
1718-1721, Level 17 Landmark North, 39 Lung Sum Avenue, Sheung Shui, New Territories, Hong Kong
(5-mins walk from MTR Sheung Shui Station Exit A4)
Investment Banking
Admiralty
Address:
Room 2602A, 26/F, Tower 1, Lippo Centre, 89 Queensway, Admiralty, Hong Kong
(3-mins walk from MTR Admiralty Exit B)
uSMART Network
uSmart Securities Limited is a corporation licensed by the Hong Kong Securities and Futures Commission (CE No.: BJA907) and is authorised to carry on Type 1 (Dealing in Securities), Type 2 (Dealing in Futures Contracts), Type 4 (Advising on Securities), Type 5 (Advising on Futures Contracts), Type 6 (Advising on Corporate Finance) and Type 9 (Asset Management) regulated activities.